Bio-Connect
IHC-P analysis of human brain tissue using GTX85036 CAPS1 antibody. Working concentration : 5 microg/ml
IHC-P analysis of human brain tissue using GTX85036 CAPS1 antibody. Working concentration : 5 microg/ml
IHC-P analysis of human brain tissue using GTX85036 CAPS1 antibody. Working concentration : 5 microg/ml

CAPS1 antibody

GTX85036
GeneTex
ApplicationsWestern Blot, ELISA, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman, Mouse, Rat
TargetCADPS
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    CAPS1 antibody
  • Delivery Days Customer
    9
  • Antibody Specificity
    Numerous isoforms of CAPS1 are known to exist. This CAPS1 antibody is predicted to be specific to CAPS1 and not recognize CAPS2.
  • Application Supplier Note
    WB: 0.5 microg/mL. IHC-P: 5 microg/mL. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    Western Blot, ELISA, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    1 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID8618
  • Target name
    CADPS
  • Target description
    calcium dependent secretion activator
  • Target synonyms
    Ca++-dependent secretion activator; Ca2+ dependent secretion activator; Ca2+-dependent activator protein for secretion; Ca2+-regulated cytoskeletal protein; CADPS1; calcium-dependent activator protein for secretion 1; calcium-dependent secretion activator 1; CAPS; CAPS1; CAPS-1; UNC-31
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDQ9ULU8
  • Protein Name
    Calcium-dependent secretion activator 1
  • Scientific Description
    CAPS1 and its related protein CAPS2 encode novel neural/endocrine-specific cytosolic and peripheral membrane proteins. Both are essential components of the synaptic vesicle priming machinery and are required for the Ca2+-regulated exocytosis of secretory vesicles; CAPS-deficienct neurons contain no or very few fusion competent synaptic vesicles, causing a selective impairment of fast phasic transmitter release. CAPS1 acts at a stage in exocytosis that follows ATP-dependent priming, which involves the essential synthesis of phosphatidylinositol 4,5-bisphosphate and is thought to be a specific regulator of large dense-core vesicle fusion. Numerous isoforms of CAPS1 are known to exist. This CAPS1 antibody is predicted to be specific to CAPS1 and not recognize CAPS2.
  • Reactivity
    Human, Mouse, Rat
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203